本次监测周期内，波司登、阿迪达斯和斯凯奇以1.89、1.82、1.53的综合热度位列榜单综合热度前三。 女鞋与时尚包包赛道以舒适化主导，文化赋能与轻奢平替成竞争核心 从品牌动态来看，女鞋与时尚包包赛道正经历从"功能导向"向"文化认同与体验驱动"的深刻转型，品牌 竞争已从价格战升级为设计、文化内涵与用户情感连接的全方位较量。 这一趋势在达芙妮集团的国际化战略中得到鲜明体现——9月26日，其子品牌DAPHNE.LAB携手中国设 计师品牌DIDU在巴黎时装周发布"就敢破格"联名系列，推出泡泡糖老爹鞋与方糖过膝靴，由郭碧婷演 绎酷感穿搭，成功将中国设计推向国际舞台。 这一事件标志着品牌从"国民女鞋"向"全球潮流品牌"的跃迁，印证了消费者对文化认同与设计独特性的 强烈需求。CHARLES & KEITH在成都开设中国首家双层旗舰店（564平方米），以"狗牙纹Hobo包"为 核心爆款（售价899元），通过高辨识度设计与亲民价格精准切入学生与职场新人市场。 9月该系列全面铺货，成为秋季现象级单品，充分展现了Z世代对"高性价比+高辨识度"产品的持续偏 好。百丽集团则通过天猫超品日"星光街区"主题，联动TATA与"黄油小熊"推 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, amidst a challenging industry environment [1] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total operating revenue of 817 million yuan, representing a year-on-year growth of 6.96% [1] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [1] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [1] Group 2: Strategic Initiatives - The company has implemented a robust strategy focusing on its unique product line, particularly in the cardiovascular and chronic disease sectors [1] - Wohuah Pharmaceutical plans to optimize its production system in 2025, enhancing operational efficiency and supply chain resilience through resource collaboration and technological upgrades [2] - The company aims to deepen its focus on proprietary products and expand its market presence while maintaining a strong financial structure for potential capital operations [2] Group 3: Market Outlook - The Chinese traditional medicine market is expected to continue its rapid growth, supported by favorable policies and the introduction of new products [2] - The company is committed to refining its management practices to improve operational efficiency and shareholder returns [2]

Core Viewpoint - Wohuah Pharmaceutical (002107.SZ) has reported a significant increase in net profit for 2025, achieving a 162.93% year-on-year growth, marking the highest increase in nearly a decade, despite a challenging industry environment [2] Group 1: Financial Performance - In 2025, Wohuah Pharmaceutical achieved total revenue of 817 million yuan, representing a year-on-year growth of 6.96% [2] - The net profit attributable to shareholders reached 95.72 million yuan, reflecting a substantial increase of 162.93% [2] - The net cash flow from operating activities increased by 40.45% year-on-year, indicating strong cash generation capabilities [2] Group 2: Strategic Initiatives - The company has maintained a "strong exclusive product line" strategy, focusing on proprietary products in the cardiovascular and chronic disease sectors [2] - Wohuah Pharmaceutical plans to implement a strategic optimization and restructuring of its production system in 2025, aiming for efficient integration and cost reduction [3] - The company intends to deepen its focus on proprietary product lines and enhance clinical value and market synergy while responding to ongoing procurement policies [3] Group 3: Future Outlook - Wohuah Pharmaceutical aims to strengthen its research and access strategies, leveraging a solid financial structure for potential capital operations around its core business [3] - The company is expected to continue benefiting from favorable policies supporting the traditional Chinese medicine market, which is projected to maintain rapid growth [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 達芙妮國際控股有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00210 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HK ...

Core Viewpoint - The control of Cangzhou Mingzhu (002108) is set to change, with Guangzhou Light Industry becoming the new controlling shareholder, and the actual controller will be the Guangzhou State-owned Assets Supervision and Administration Commission [1][2]. Group 1: Share Transfer Details - Guangzhou Light Industry will acquire 166,539,465 shares from Dongsu Group, representing 10.10% of the total share capital as of the agreement date [1]. - Dongsu Group and its concerted parties will delegate voting rights for an additional 159,609,160 shares (9.68% of total share capital) to Guangzhou Light Industry, giving it a total voting power of 19.78% in the company [1][2]. - As of the announcement date, Dongsu Group holds 313,912,903 shares (19.04% of total share capital) and is the current controlling shareholder [2]. Group 2: Company Background and Performance - Cangzhou Mingzhu was established in 1995 and operates six wholly-owned subsidiaries, two holding subsidiaries, two branches, and three associated companies, with major industrial parks in Cangzhou and production bases in Shandong, Anhui, and Chongqing [2]. - The company has faced performance pressure in recent years, with negative growth in net profit since the third quarter of 2023, although there was a slight increase of 0.99% in net profit year-on-year for the first three quarters, and revenue grew by 5.90% to 2.078 billion yuan [2][3]. - The sales revenue of PE pipe products has decreased compared to the previous year, while BOPA film products have seen an increase in both sales volume and revenue, with improved profitability [3]. Group 3: Market Reaction - Following the announcement, Cangzhou Mingzhu's stock opened nearly 4% higher on December 16 but later retreated, closing with a 1.29% increase at 4.72 yuan per share, giving it a market capitalization of 7.78 billion yuan [3].

该信息由智通财经网提供 智通财经APP讯，达芙妮国际(00210)发布公告，执行董事王俊刚先生，为了投放更多时间于彼之其他事 务，已调任为非执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

达芙妮国际(00210)发布公告，执行董事王俊刚先生，为了投放更多时间于彼之其他事务，已调任为非 执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

格隆汇12月11日丨达芙妮国际(00210.HK)公告，执行董事王俊刚，为了投放更多时间于彼其他事务，已 调任为非执行董事并辞任公司营运总监，自2025年12月11日起生效。 ...

DAPHNE INTERNATIONAL HOLDINGS LIMITED 達 芙 妮 國 際 控 股 有 限 公 司* ( 於開曼群島註冊成立之有限公司 ) (股份代號： 210) 董事名單與其角色和職能 達芙妮國際控股有限公司之董事會﹝「董事會」﹞成員載列如下： 執行董事： | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 張智凱先生 | - | M | M | | 張智喬先生 | - | - | - | | 張椀絢女士 | - | - | - | | 王俊剛先生 | - | - | - | | 韓炳祖先生 | C | M | M | | 談大成先生 | M | C | M | | 許文冠女士 | M | M | C | C – 有關委員會之主席 M – 有關委員會之成員 香港，二零二五年十二月十一日 * 僅供識別 張智凱先生 ﹝主席﹞ 張智喬先生 ﹝行政總裁﹞ 張椀絢女士 非執行董事： 王俊剛先生 獨立非執行董事： 韓炳祖先生 談大成先生 許文冠女士 董事會設立三個委員會。下表提供各董事會成員在該等委員會中所 ...